Chiltern Expands In Argentina
Oscar Podesta, executive director of Chiltern in Latin America, said: “Our office, strategically located in suburban Pilar, is a natural next step to our development in Argentina. The
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.
Temperature excursions can inhibit the clinical supply chain, resulting in investigational products being delayed or quarantined and not made available for immediate use at the study site. Excursions